SWOG clinical trial number
SWOG-8239
Evaluation of Spirogermanium (NSC-192965) in Central Nervous System Tumors
Closed
Phase
Published
Abbreviated Title
Evaluation of Spirogermanium (NSC-192965) in Central Nervous System Tumors
Activated
01/31/1983
Publication Information Expand/Collapse
1987
Phase II trial of spirogermanium in central nervous systemtumors: A Southwest Oncology Group Study.
1985
A Phase II study of spirogermanium in central nervous system tumors: A Southwest Oncology Group study.
1984
Phase II clinical trial of spirogermanium in central nervous system tumors: A Southwest Oncology Group study.